201 related articles for article (PubMed ID: 3025826)
1. A fragment of vasoactive intestinal peptide, VIP(10-28), is an antagonist of VIP in the colon carcinoma cell line, HT29.
Turner JT; Jones SB; Bylund DB
Peptides; 1986; 7(5):849-54. PubMed ID: 3025826
[TBL] [Abstract][Full Text] [Related]
2. Phorbol ester induces loss of VIP stimulation of adenylate cyclase and VIP-binding sites in HT29 cells.
Bozou JC; Couvineau A; Rouyer-Fessard C; Laburthe M; Vincent JP; Kitabgi P
FEBS Lett; 1987 Jan; 211(2):151-4. PubMed ID: 3026847
[TBL] [Abstract][Full Text] [Related]
3. HT 29, a model cell line: stimulation by the vasoactive intestinal peptide (VIP); VIP receptor structure and metabolism.
Marchis-Mouren G; Martin JM; Luis J; el Battari A; Muller JM; Marvaldi J; Pichon J
Biochimie; 1988 May; 70(5):663-71. PubMed ID: 2844304
[TBL] [Abstract][Full Text] [Related]
4. Vasoactive intestinal peptide receptor antagonists in rat seminal vesicle membranes.
Rodríguez-Pena MS; Guijarro LG; Prieto JC
Eur J Pharmacol; 1991 Nov; 208(3):207-12. PubMed ID: 1663044
[TBL] [Abstract][Full Text] [Related]
5. Vasoactive intestinal polypeptide receptor VPAC(1) subtype is predominant in rat prostate membranes.
Juarranz MG; De Neef P; Robberecht P
Prostate; 1999 Sep; 41(1):1-6. PubMed ID: 10440869
[TBL] [Abstract][Full Text] [Related]
6. Cycloheximide induces accumulation of vasoactive intestinal peptide (VIP) binding sites at the cell surface of a human colonic adenocarcinoma cell line (HT29-D4). Evidence for the presence of an intracellular pool of VIP receptors.
Luis J; Martin JM; el Battari A; Fantini J; Giannellini F; Marvaldi J; Pichon J
Eur J Biochem; 1987 Sep; 167(2):391-6. PubMed ID: 3040409
[TBL] [Abstract][Full Text] [Related]
7. Development of vasoactive intestinal peptide-responsive adenylate cyclase during enterocytic differentiation of Caco-2 cells in culture. Evidence for an increased receptor level.
Laburthe M; Rousset M; Rouyer-Fessard C; Couvineau A; Chantret I; Chevalier G; Zweibaum A
J Biol Chem; 1987 Jul; 262(21):10180-4. PubMed ID: 3038870
[TBL] [Abstract][Full Text] [Related]
8. Vasoactive intestinal peptide and intraocular pressure: adenylate cyclase activation and binding sites for vasoactive intestinal peptide in membranes of ocular ciliary processes.
Mittag TW; Tormay A; Podos SM
J Pharmacol Exp Ther; 1987 Apr; 241(1):230-5. PubMed ID: 3033201
[TBL] [Abstract][Full Text] [Related]
9. Effect of freezing on the coupling of VIP receptors to adenylate cyclase in rat liver membranes.
Robberecht P; Waelbroeck M; De Neef P; Camus JC; Gourlet P; Christophe J
Life Sci; 1988; 42(5):505-10. PubMed ID: 2828794
[TBL] [Abstract][Full Text] [Related]
10. Identification of nuclear receptors for VIP on a human colonic adenocarcinoma cell line.
Omary MB; Kagnoff MF
Science; 1987 Dec; 238(4833):1578-81. PubMed ID: 2825352
[TBL] [Abstract][Full Text] [Related]
11. [D-Phe4]peptide histidine-isoleucinamide ([D-Phe4]PHI), a highly selective vasoactive-intestinal-peptide (VIP) agonist, discriminates VIP-preferring from secretin-preferring receptors in rat pancreatic membranes.
Robberecht P; Coy DH; De Neef P; Camus JC; Cauvin A; Waelbroeck M; Christophe J
Eur J Biochem; 1987 Jun; 165(2):243-9. PubMed ID: 3036504
[TBL] [Abstract][Full Text] [Related]
12. Characterization of binding sites for VIP-related peptides and activation of adenylate cyclase in developing pancreas.
Le Meuth V; Farjaudon N; Bawab W; Chastre E; Rosselin G; Guilloteau P; Gespach C
Am J Physiol; 1991 Feb; 260(2 Pt 1):G265-74. PubMed ID: 1847591
[TBL] [Abstract][Full Text] [Related]
13. Homologous regulation of adenylate cyclase-coupled receptors for vasoactive intestinal peptide (VIP) on human mononuclear leucocytes.
Wiik P
Regul Pept; 1988 Apr; 20(4):323-33. PubMed ID: 2835796
[TBL] [Abstract][Full Text] [Related]
14. Interaction of a bovine thymic peptide extract with vasoactive intestinal peptide (VIP) receptors.
Guerrero JM; Goberna R; Molinero P; Jimenez J; Calvo JR
Biosci Rep; 1986 Jun; 6(6):579-84. PubMed ID: 3021253
[TBL] [Abstract][Full Text] [Related]
15. The activation of adenylate cyclase by pituitary adenylate cyclase activating polypeptide (PACAP) via helodermin-preferring VIP receptors in human SUP-T1 lymphoblastic membranes.
Gourlet P; De Neef P; Woussen-Colle MC; Vandermeers A; Vandermeers-Piret MC; Robberecht P; Christophe J
Biochim Biophys Acta; 1991 Jul; 1066(2):245-51. PubMed ID: 1649637
[TBL] [Abstract][Full Text] [Related]
16. Interaction of thymic peptide thymosin alpha 1 with vasoactive intestinal peptide (VIP) receptors.
Calvo JR; Goberna R; Guerrero JM
Biosci Rep; 1986 Aug; 6(8):727-33. PubMed ID: 3028522
[TBL] [Abstract][Full Text] [Related]
17. Effects of vasoactive intestinal peptide on adenosine 3',5'-monophosphate, ornithine decarboxylase, and cell growth in a human colon cell line.
Yu D; Seitz PK; Selvanayagam P; Rajaraman S; Townsend CM; Cooper CW
Endocrinology; 1992 Sep; 131(3):1188-94. PubMed ID: 1324153
[TBL] [Abstract][Full Text] [Related]
18. Cholesterol modulation of membrane fluidity and VIP receptor/effector system in rat prostatic epithelial cells.
Carmena MJ; Hueso C; Guijarro LG; Prieto JC
Regul Pept; 1991 May; 33(3):287-97. PubMed ID: 1652781
[TBL] [Abstract][Full Text] [Related]
19. Vasoactive intestinal peptide stimulation of human renal adenylate cyclase in vitro.
Charlton BG; Neal DE; Simmons NL
J Physiol; 1990 Apr; 423():475-84. PubMed ID: 2167366
[TBL] [Abstract][Full Text] [Related]
20. Restricted localization of functional vasoactive intestinal peptide (VIP) receptors in in vitro differentiated human colonic adenocarcinoma cells (HT29-D4).
Fantini J; Martin JM; Luis J; Rémy L; Tirard A; Marvaldi J; Pichon J
Eur J Cell Biol; 1988 Aug; 46(3):458-65. PubMed ID: 2846304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
